Sonoma Pharmaceuticals (SNOA) Common Equity (2011 - 2026)

Sonoma Pharmaceuticals' Common Equity history runs 16 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Common Equity fell 29.83% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 29.83% decrease from a year earlier, with the FY2026 full-year figure at $3.1 million, down 29.83% from the prior year.
• Common Equity retreated to $3.1 million in Q1 2026 per SNOA's latest filing, from $3.4 million in the prior quarter.
• Across five years, Common Equity topped out at $8.7 million in Q1 2022 and bottomed at $3.1 million in Q1 2026.
• The 5-year median for Common Equity is $5.6 million (2022), against an average of $5.7 million.
• Biggest YoY gain for Common Equity was 72.24% in 2022; the steepest drop was 50.23% in 2022.
• Year by year, Common Equity stood at $5.6 million in 2022, then increased by 20.38% to $6.7 million in 2023, then fell by 27.23% to $4.9 million in 2024, then slipped by 29.53% to $3.4 million in 2025, then fell by 9.82% to $3.1 million in 2026.
• Per Business Quant, the three latest SNOA Common Equity figures stand at $3.1 million (Q1 2026), $3.4 million (Q4 2025), and $3.8 million (Q3 2025).